- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Long-Term Follow-Up from CheckMate 9LA at ASCO 2024
A key opinion leader examines the overall survival data from the CheckMate 9LA study, which evaluated nivolumab plus ipilimumab plus chemotherapy in metastatic non-small cell lung cancer patients, and explores how the long-term follow-up results inform treatment decisions in this setting.
EP: 1.Expert Insights on NSCLC: Unmet Needs and Innovations from ASCO 2024
EP: 2.ASCO 2024: Key Findings of the LAURA Trial on Osimertinib for EGFR-Mutated NSCLC
EP: 3.Evaluating Amivantamab and Lazertinib: Key Findings from the CHRYSALIS-2 Study at ASCO 2024
EP: 4.Insights from the TROPION-Lung05 Trial at ASCO 2024
EP: 5.Long-Term Follow-Up from CheckMate 9LA at ASCO 2024
EP: 6.ASCO 2024 and Beyond: Addressing NSCLC Unmet Needs and Future Research Directions
Video content above is prompted by the following questions:
- Discuss the data that was presented at the ASCO 2024 on overall survival from the CheckMate 9LA study with the use of nivolumab + ipilimumab + chemotherapy in patients with metastatic NSCLC.
- What are your key takeaways from this study?
- How do you think the long term follow up data supports decision-making in metastatic NSCLC?
AI in Oncology: Opportunities and Challenges for NSCLC
January 1st 2025Ryan Nguyen, DO, University of Illinois Chicago, highlights the importance of personalized care for patients who have non–small cell lung cancer (NSCLC) and the potential of artificial intelligence (AI) in oncology, while cautioning against its limitations, including the risk of unsupported recommendations.
Read More
ICYMI: Highlights From AMCP Nexus 2024
December 26th 2024Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.
Read More
Precision Oncology in NSCLC: Overcoming Patient Selection Barriers
December 23rd 2024Ryan Nguyen, DO, physician and researcher at the University of Illinois Chicago, emphasizes the transformative impact of immunotherapy in non–small cell lung cancer (NSCLC) and the need for precise biomarkers and equitable access to advanced treatments through systemic testing protocols.
Read More
